Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Delayed Quote USD

Aclaris Therapeutics, Inc. (ACRS)

Compare
1.1400
+0.0100
+(0.88%)
At close: April 17 at 4:00:01 PM EDT
1.0772
-0.06
(-5.51%)
After hours: April 17 at 6:31:36 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
18,720
18,720
31,249
29,752
6,761
Cost of Revenue
15,458
15,458
18,081
11,960
4,713
Gross Profit
3,262
3,262
13,168
17,792
2,048
Operating Expense
55,789
55,789
129,482
102,946
67,432
Operating Income
-52,527
-52,527
-116,314
-85,154
-65,384
Other Income Expense
-79,538
-79,538
27,466
-1,754
-25,481
Pretax Income
-132,065
-132,065
-88,848
-86,908
-90,865
Tax Provision
--
--
-367
--
--
Net Income Common Stockholders
-132,065
-132,065
-88,481
-86,908
-90,865
Diluted NI Available to Com Stockholders
-132,065
-132,065
-88,481
-86,908
-90,865
Basic EPS
-0.52
-1.71
-1.27
-1.33
-1.60
Diluted EPS
-0.52
-1.71
-1.27
-1.33
-1.60
Basic Average Shares
71,156.8440
77,296.6650
69,808.8550
65,213.9440
56,730.5830
Diluted Average Shares
71,156.8440
77,296.6650
69,808.8550
65,213.9440
56,730.5830
Total Operating Income as Reported
-141,932
-141,932
-97,357
-89,854
-89,723
Total Expenses
71,247
71,247
147,563
114,906
72,145
Net Income from Continuing & Discontinued Operation
-132,065
-132,065
-88,481
-86,908
-90,865
Normalized Income
-42,660
-42,660
-107,359.6953
-82,208
-66,526
EBIT
-52,527
-52,527
-116,314
-85,154
-65,384
EBITDA
-51,720
-51,720
-115,451
-84,357
-64,461
Reconciled Cost of Revenue
15,458
15,458
18,081
11,960
4,713
Reconciled Depreciation
807
807
863
797
923
Net Income from Continuing Operation Net Minority Interest
-132,065
-132,065
-88,481
-86,908
-90,865
Total Unusual Items Excluding Goodwill
-89,405
-89,405
18,957
-4,700
-24,339
Total Unusual Items
-89,405
-89,405
18,957
-4,700
-24,339
Normalized EBITDA
37,685
37,685
-134,408
-79,657
-40,122
Tax Rate for Calcs
--
--
0
--
--
Tax Effect of Unusual Items
--
--
78.3047
--
--
12/31/2021 - 10/6/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VCYT Veracyte, Inc.
31.14
-1.24%
 
SHC Sotera Health Company
10.48
-0.10%
 
NDRA ENDRA Life Sciences Inc.
3.6700
+8.90%
 
ISPC iSpecimen Inc.
1.2350
-6.44%
 
IJF.MU Icon PLC
127.30
0.00%
 
NRC.SG Neuronetics Inc
3.2450
+2.37%
 
MEDP.MX Medpace Holdings, Inc.
5,869.75
0.00%
 
NOTV Inotiv, Inc.
1.6400
-0.61%
 
DIA.WA Diagnostyka S.A.
148.20
+0.14%
 
LO3A.F Lonza Group AG
58.00
+2.65%